Intracranial metastasis from primary transitional cell carcinoma of female urethra: case report & review of the literature by Moon, Kyung-Sub et al.
CASE REPORT Open Access
Intracranial metastasis from primary transitional
cell carcinoma of female urethra: case report &
review of the literature
Kyung-Sub Moon
1, Shin Jung
1*, Kyung-Hwa Lee
2, Eu Chang Hwang
3, In-Young Kim
1
Abstract
Background: Transitional cell carcinoma (TCC) of the female urethra is a rare urological malignancy, and
intracranial metastasis of this cancer has not yet been reported in the literature. This review is intended to present
a case of multiple intracranial metastasis in a female patient with a remote history of primary urethral TCC.
Case Presentation: A 49-year-old woman, presented with a prolapsed mass in urethral orifice that was diagnosed
as primary urethral TCC with distant lung and multiple bone metastases. The patient subsequently underwent
chemotherapy under various regimens. A year later, the patient developed headache and vomiting which as was
found to be due to multiple intracranial metastasis. The patient underwent surgical resection of the largest lesion
located on the cerebellum, and consecutively gamma knife radiosurgery was performed for other small-sized
lesions. Pathological examination of the resected mass revealed a metastatic carcinoma from a known urethral TCC.
Serial work-up of systemic metastasis revealed concomitant aggravation of lung, spleen, and liver metastasis. The
patient died of lung complication 2 months after the diagnosis of brain metastasis.
Conclusion: To the best of our knowledge, this is the first reported case of cerebral metastasis from primary
urethral TCC, with pathological confirmation. As shown in intracranial metastasis of other urinary tract carcinoma,
this case occurred in the setting of uncontrolled systemic disease and led to dismal prognosis in spite of
aggressive interventional modalities.
Background
Primary urethral carcinoma is a rare entity, accounting
for only 0.02% of all female cancers [1]. The overall
annual incidence for women is 1.5 per million and it
increases progressively with age [2]. Although there
have been some debates in the exact proportion of
pathological subtypes of female urethral carcinoma,
transitional cell carcinoma (TCC) is one of the most fre-
quently observed subtypes [2,3].
Intracranial metastasis from TCC of urinary system is
reported as rare events [4]. Majority of the reported
cases of intracranial metastasis from TCC originated
from bladder and upper urinary tract [5-12]. To the best
of our knowledge, intracranial metastasis from primary
urethral TCC has not yet been reported in the literature.
In this paper, we present an extremely rare case that
underwent surgical resection and gamma knife radiosur-
gery for multiple intracranial metastases originating
from primary urethral TCC.
Case Presentation
A 50-year-old woman was admitted with headache and
vomiting for 2 days. One year prior to the present
admission, she had visited the department of urology for
the treatment of a prolapsed mass in urethral orifice.
Cystoscopy revealed a proximal urethral mass with an
unremarkable bladder. Based on the pelvic computed
tomography (CT) (Figure 1), cystoscopy and biopsy find-
ings (Figure 2), she was diagnosed as a primary urethral
TCC. Systemic evaluation including positron emission
tomography - CT, bone scan, and magnetic resonance
(MR) images revealed distant metastases in both the
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ted with five courses of M-VAC chemotherapy protocol
(45㎎ methotraxate, 4.5㎎ vinblastin, 45㎎ adriamycin,
110㎎ cisplatin). On follow-up, persistent progression of
lung and liver metastasis was observed, thus the chemo-
regimens had been changed into the second courses of
GC protocol (1600㎎ gemcitabine and 100㎎ cisplatin),
followed by the third courses of PC protocol (120㎎
palcitaxel and 100㎎ cisplatin).
On physical examination at the admission, no neuro-
logical signs were observed. Brain MR imaging study
demonstrated a 3㎝-sized enhanced lesion on the right
cerebellar hemisphere with ventricular effacement.
Several smaller enhanced lesions were also noted on
the cerebral and cerebellar hemisphere. Majority of
the lesions showed an internal hyperintensity on the
T1-weighted MR due to hemorrhage and peritumoral
edema as well (Figure 3). After corticosteroid treatment,
surgery was performed using a suboccipital approach for
the largest lesion on the right cerebellar hemisphere.
The mass was removed in toto and the postoperative
course was uneventful. The pathological findings were
consistent with the diagnosis of TCC (Figure 4).
One week after surgery, the patient underwent gamma
knife radiosurgery for the remaining multiple metastatic
lesions. Systemic re-evaluation revealed concomitant
aggravation of lung, spleen, and liver metastases.
Although adjuvant chemotherapy was recommended for
systemic cancer control, patient’s family opted for a con-
servative medical support. The patient died of aggrava-
tion of lung metastasis two months after the diagnosis
of brain metastasis.
Discussion
As per the description of primary urethral carcinoma by
Boiven and Deuges published in 1833, these tumors
constitute a very small proportion, equivalent to lesser
than 1% of all female urothelial cancer [13]. It has been
regarded that urethral carcinoma is the only urological
Figure 1 Enhanced pelvic CT scan demonstrates a
heterogeneously enhanced mass on female urethra.
Figure 2 Microphotograph of the urethral mass revealed
typical features of TCC including ramifying papillae, high
nuclear/cytoplasmic ratio, and brisk mitotic activity
(hematoxylin-eosin, × 200).
Figure 3 Brain MR imaging showed multiple heterogeneously
enhanced lesions. The largest lesion, seen in the right cerebellar
hemisphere, was later surgically resected.
Moon et al. BMC Cancer 2011, 11:23
http://www.biomedcentral.com/1471-2407/11/23
Page 2 of 5cancer that is more common in female than in male
[14]. However, in a large population-based study, the
incidence of primary urethral carcinoma is relatively
higher in men and black population in the United State
[2]. The incidence of predominant pathological type in
primary urethral carcinoma still remains debatable pri-
marily due to rarity of this entity. In contrary to the pre-
vious reports describing that squamous cell carcinoma
to be the leading type [14], it has been observed that
TCC is encountered more frequently than squamous
cell carcinoma and adenocarcinoma [2].
The common mode of metastasis is hematogenous
and the frequently observed sites of this metastasis in
renal TCC are the lung, liver, lymph node, bone, adrenal
glands, spleen, and intestine [15]. Although there is
minimal information on the distant metastasis of pri-
mary urethral TCC, this cancer would follow the similar
characteristics of renal TCC, as shown in a small-patient
series [3]. Cerebral metastasis has been reported to be
occurring in less than 1% of patients with TCC [7]. Cur-
rently, the incidence of cerebral metastasis has increased
up to 3% after clinical application of chemotherapy for
TCC in the urinary tract system. This could be attribu-
ted to the long-term systemic remission that is achieved
by chemotherapeutic agents without penetration
through the blood-brain barrier [6]. Nevertheless,
besides bladder origin, only few reported cases demon-
strated cerebral metastasis from TCC in other urinary
tract system [5,10,11]. To the best of our knowledge,
this is the first reported case of cerebral metastasis from
primary urethral TCC, with pathological confirmation.
Based on the review of the literature [5-12], cerebral
metastasis presented as one of the features in systemic
progression of urothelial TCC but it could occur in the
patient with systemic control, and even as an initial
manifestation [7,8]. The interval from primary diagnosis
to the cerebral metastasis was 0 to 69 months, and it
generally developed within 3 years. Although the pre-
vious reports have been showing that majority of the
reported cases demonstrated multiplicity, solitary cere-
bral metastasis does not seem to be infrequent
[6,8,11,12].
The treatment for cerebral metastasis of TCC may fol-
low the general guidelines as for the metastatic brain
tumors. For a single large-sized lesion (> 3cm), espe-
cially with a mass effect (> 1cm midline shift), surgical
resection should be considered with/without adjuvant
whole brain radiotherapy (WBRT). WBRT has been
generally accepted as the standard treatment for multi-
ple cerebral metastases. However, considering cognitive
deficits after WBRT and the better results of radiosur-
gery, radiosurgery would play a more important role for
the treatment of metastatic brain tumors. Although the
role of surgical resection for multiple brain metastases
has not been established, surgery has been performed in
cases with large lesions or significant mass effects and in
cases where two or more lesions are accessible through
a single craniotomy approach [16]. Cerebellar metastasis
is often more life-threatening than brain metastasis in
other locations since it can cause hydrocephalus, irrever-
sible brainstem compression, and tonsilar or upward
herniation. Clinical picture could worsen dramatically
within a few days and deteriorate acutely on radiation
therapy [17]. Although survival has been reported to be
worse in the cerebellar metastasis than that in cerebral
metastasis [17,18], surgical resection can produce a sig-
nificant survival gain with clinical improvement [19-21].
Yoshida & Takahashi [21] reported that the median sur-
vival of patients who underwent surgical resection and
postoperative radiation therapy was 30.5 months, and
that the median survival was 20.5 months even for those
who received surgical resection only. Despite controver-
sies, such an aggressive local control for cerebellar
metastasis may provide a better outcome in those
selected patients with single lesion, stable systemic dis-
ease, non-lung cancer origin, or high performance status
[19-21]. In patients with multiple lesions, poor perfor-
mance status (KPS < 70) or uncontrolled systemic dis-
ease, surgical indications are questionable. Postoperative
complication rate has been reported to be relatively high
with surgical resection in cases with cerebellar metasta-
sis [20]. This can be explained by the fact that soft and
fragile tissue nature of the cerebellum causes difficulty
in bleeding control of tumor bed and leads to small-size
hematoma or contusion. Such lesions in the supraten-
torial location are generally negligible from clinical
aspects. In a posterior fossa surgery, however, even
small increase of volume in space occupying lesion can
Figure 4 Microphotograph of the brain mass revealed
metastatic carcinoma with increased pleomorphism and
mitotic activity which was nearly identical to the urethral mass
(hematoxylin-eosin, × 200).
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reoperation.
The current case had showed unfavorable factors in
determining surgical resection, such as multiplicity in
brain metastasis and uncontrolled systemic disease.
Considering the questionable survival benefit and high
incidence of postoperative complications, surgical resec-
tion for a large cerebellar lesion could seem to be exces-
sive as a treatment option. The current patient was
young and regularly received systemic treatments, and,
most importantly, demonstrated high performance sta-
tus without definitive neurological signs. Of aforemen-
tioned prognostic factors, high performance status was
the most significant parameter in choosing surgical
resection for treatment option [20,21]. We authors
believed that an aggressive treatment for brain and sys-
temic lesions should not be limited by the occurrence of
the cerebellar metastasis especially in patients with good
performance. One week after radiosurgery following
operation, the patient was discharged home without any
neurological deficit. However, the patient did not have
the opportunity to get further systemic treatment and
died of lung metastasis that had progressed rapidly.
Although it is difficult to presume survival benefit of
additional systemic chemotherapy in this case, well-con-
trolled brain lesions would allow trying further systemic
cancer control.
In selected cases with single brain lesion and well con-
trolled systemic cancer, aggressive treatment including
complete surgical resection can prolong the survival and
improve the life quality. Nonetheless, once the cerebral
metastasis occurred in TCC of urinary tract system,
the prognosis is poor, especially in the case with multi-
ple cerebral lesions and/or uncontrolled systemic
disease [6,7].
Conclusion
In conclusion, urethral TCC in female, a very rare can-
cer, can metastasize to the brain in uncontrolled sys-
temic state and result in dismal prognosis despite of
aggressive treatment, as observed in other urinary tract
TCC.
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